ImmunityBio, Inc.
IBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $3 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $2 | $3 | $3 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 21.3% | 60% | 118.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 87.1% | 99.5% | 99.6% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -111.6% | -225.3% | -588.5% | -531.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -209.8% | -350.3% | -784.9% | -783.4% |
| EPS Diluted | -0.071 | -0.1 | -0.15 | -0.09 |
| % Growth | 29% | 33.3% | -66.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |